Table of Content


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Test Type
3.3. Snippet by Spread
3.4. Snippet by Stage
3.5. Snippet by End User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Advancements in Diagnostic Technologies
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. False Positive Results
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Epidemiology
5.6. Number of Breast Cancer Tests Conducted in US, EU5, Japan, China and India 2022-2030
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Cancer Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Invasive lobular breast cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Ductal carcinoma in situ (DCIS)
7.4. Triple-negative breast cancer
7.5. Inflammatory breast cancer
7.6. Others
8. By Test Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.1.2. Market Attractiveness Index, By Test Type
8.2. Clinical Breast Exam*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Imaging Tests
8.3.1.1. MRI
8.3.1.2. Ultrasound
8.3.1.3. PET
8.3.1.4. Others
8.4. Blood Tests
8.5. Biopsies
8.5.1.1. Excisional biopsy
8.5.1.2. Incisional biopsy
8.5.1.3. Core biopsy
8.5.1.4. Fine-needle aspiration (FNA) biopsy
8.5.1.5. Others
8.6. Others
9. By Spread
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
9.1.2. Market Attractiveness Index, By Spread
9.2. Local*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Regional
9.4. Distant
10. By Stage
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.1.2. Market Attractiveness Index, By Stage
10.2. Stage I*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Stage II
10.4. Stage III
10.5. Stage IV
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals and Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Diagnostic Centers
11.4. Cancer Research Institutes
11.5. Medical Research Centers and Institutes
11.6. Ambulatory Surgical Centers
11.7. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Siemens Healthineers AG
14.1.1. Company Overview
14.1.2. Product Type Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Kheiron Medical Technologies
14.3. Bio-Rad Laboratories
14.4. Hologic, Inc.
14.5. Quest Diagnostics Incorporated
14.6. FUJIFILM Holdings Corporation
14.7. GE Healthcare
14.8. Illumina, Inc.
14.9. Metaltronica SpA
14.10. Carestream Health
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us